US FDA Warns Supplement Own Labeler About Reliance On Manufacturer For Compliance

Revival Products’ GMP deficiencies concerned work and training of its quality control staff, including failing to document review and approval for release of any packaged and labeled supplement for distribution and destroying returned products without review.

Stamp with word warning inside,vector illustration

One of the US Food and Drug Administration’s latest warning letters revisits a topic commonly noted in dietary supplement facility inspections but absent from warnings posted during the COVID-19 pandemic: contract manufacturers don’t ensure own labelers’ regulatory compliance.

The Office of Regulatory Affairs East Division 3 district office in Atlanta found good manufacturing practice and labeling problems during...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation